Clinical Trial Update: EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of crizotinib in ROS1-translocated lung cancer (EU CROSS) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: University of Cologne | Conditions: Lung Cancer, Adenocarcinoma | Phase 2 | Status: COMPLETED